REGENXBIO Q2 net loss $53M; advances RGX-202 pivotal and RGX-121 BLA

REGENXBIO Inc.

2024-Q2 EPS reported -$2.41 revenue$37,917,000

Q2 2024 net loss of $53.0M ($1.05 per share); revenue $22.3M (up 12% YoY) on Zolgensma royalties.
Cash $327.3M at June 30, 2024; runway into 2026, excluding potential $200M AbbVie milestone.
RGX-202 (Duchenne): consistent high microdystrophin expression; EOP2 supports accelerated approval; pivotal trial start Q4 2024.
RGX-121 (MPS II): rolling BLA submission begins Q3 2024 under accelerated approval pathway.
ABBV-RGX-314 (diabetic retinopathy): EOP2 meeting accelerated to Q4 2024; global pivotal trial planned H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.